Table 1:
Baseline characteristics of all participants included in the analysis of the VitaVasK study.
| Characteristics | Controls (n = 23) | Vitamin K1 (n = 17) |
|---|---|---|
| Female, n (%) | 6 (26) | 6 (38) |
| Age (years) | 64.4 ± 13.3 | 62.5 ± 12.3 |
| Dialysis vintage (months) | 82.1 ± 65.6 | 65.2 ± 56.6 |
| Body mass index (kg/m2) | 27.4 ± 6 | 26.7 ± 4.9 |
| Smoking status,an (%)Current or ex-smokerNon-smoker | 12 (55)10 (46) | 11 (69)5 (31) |
| Systolic blood pressureb (mmHg) | 141.9 ± 18.4 | 138.9 ± 19.7 |
| Diastolic blood pressureb (mmHg) | 69.6 ± 13.6 | 75.0 ± 16.7 |
| Diabetes mellitus, n (%) | 8 (34.8) | 2 (11.8) |
| Haemoglobin A1c (%) | 5.5 ± 0.8 | 5.5 ± 1 |
| International normalized ratio | 0.98 ± 0.09 | 0.96 ± 0.07 |
| Haemoglobin (g/l) | 111.5 ± 8.6 | 109.9 ± 9.9 |
| Serum ionized calcium (mmol/l) | 1.1 ± 0.1 | 1.1 ± 0.2 |
| Serum phosphate (mmol/l) | 1.8 ± 0.5 | 1.9 ± 1.2 |
| Serum intact parathyroid hormone (ng/l) | 265.3 ± 306.7 | 536.1 ± 426.8 |
| Serum alkaline phosphatase (U/I) | 93 ± 52 | 93 ± 48 |
| Bone-specific alkaline phosphatase (U/I) | 27 ± 23 | 36 ± 33 |
| 25-hydroxyvitamin D3 (μg/l) | 45.2 ± 20.2 | 31.7 ± 19.7 |
| Serum total magnesium (mmol/l) | 0.9 ± 0.1 | 1 ± 0.2 |
| Total cholesterol (mg/dl) | 169.4 ± 41.3 | 166.7 ± 34.3 |
| C-reactive protein (mg/l) | 5.5 ± 8.6 | 4.7 ± 4.3 |
| Statin therapy, n (%) | 11 (47.8) | 8 (47.0) |
| Native vitamin D therapy, n (%) | 18 (85.7) | 14 (93.3) |
| Vitamin D receptor agonist therapy, n (%) | 15 (71.4) | 8 (53.3) |
| Calcium-free phosphate binder therapy, n (%) | 12 (65.2) | 13 (82.4) |
| Calcium-containing phosphate binder therapy, n (%) | 15 (71.4) | 9 (60.0) |
| Calcimimetic therapy, n (%) | 9 (42.9) | 7 (46.7) |
| Months from baseline CT to planned 12-month CT | 12.6 ± 1.3 | 12.7 ± 1.4 |
| Months from baseline CT to planned 18-month CT | 19.6 ± 1.4 | 18.3 ± 1.1 |
| Coronary artery disease, n (%) | 11 (34.8) | 8 (41.8) |
| TAC (mm3) | 4864.6 ± 4792.0 | 4830.3 ± 10 621.3 |
| Aortic valve calcification (mm3) | 148.2 ± 246.3 | 133.5 ± 171.0 |
| CAC (mm3) | 1886.9 ± 1143.1 | 1550.5 ± 1419.7 |
| Mitral valve calcification (mm3) | 1063.1 ± 2237.1 | 936.6 ± 1764.8 |
Values are presented as mean ± SD unless stated otherwise. All calcification values are volume scores.
aInformation on smoking status was missing for one person in each group.
bPre-dialysis blood pressure after long interdialytic interval.